Matthew M. Schwartz
Independent DirectorDr. Matthew M. Schwartz, M.D. serves as an Independent Director at IMAC Holdings, Inc. since June 26, 2024. He is Independent Director of Avant Diagnostics, Inc. (formerly known as Theralink Technologies, Inc.). from April 04, 2022. He is a Radiation Oncologist with extensive experience in the Oncology and Biotechnology industries. He served on the Board of Directors of CCCN. He also co-founded the Las Vegas Cyberknife. He serves as the Chairman of the Board of Managers of Las Vegas Cyberknife. Dr. Schwartz has extensive leadership experience in the Oncology space and has served on the Radiation Oncology Leadership Council of the US Oncology Network. He is well-versed in Precision Oncology for cancer patients. He trained at McGill University, where he was Chief Resident and Yale-New Haven Hospital. He was named Alumni of the Year by the UNLV College of Sciences. He received his MD from the University of Nevada School of Medicine and he was a Resident at Yale University Department of Internal Medicine and McGill University School of Medicine where he was Chief Resident. He served on the Radiation Oncology Leadership Council of US Oncology. He has been the Principal Investigator on Clinical Research Studies in Oncology.
Positions
- Company NameIMAC Holdings, Inc.Stock CodeBACKPositionIndependent Director
